Institutional
venBio Partners LLC
CIK 0001776382
$280.6M
Reported AUM
6
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · venBio Partners LLC · Q1 2026
AI · grounded in 13F
venBio Partners LLC increased its position in ALXO by 32.83%. The fund trimmed its holdings in ARTV by 18.07% and reduced its stake in ALMS by 1.98%. The fund ended the period with 6 positions and total assets under management of $280.55M.
Portfolio · Q1 2026
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PHVS | PHARVARIS N V | $33.62 | 3.05% | 67.35% | 65.78% | $131.1M | 46.71% | — | HELD |
| 2 | ALMS | ALUMIS INC | $27.42 | 3.94% | 563.92% | 122.93% | $99.8M | 35.56% | — | HELD |
| 3 | ALXO | ALX ONCOLOGY HLDGS INC | $1.97 | 1.03% | 275.48% | -97.22% | $25.8M | 9.21% | — | HELD |
| 4 | HRMY | HARMONY BIOSCIENCES HLDGS IN | $35.31 | -1.53% | 1.89% | 3.42% | $13.7M | 4.88% | — | HELD |
| 5 | LYEL | LYELL IMMUNOPHARMA INC | $13.40 | 3.32% | 17.70% | -95.89% | $6.8M | 2.41% | — | HELD |
| 6 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $10.45 | 4.34% | 254.06% | -13.17% | $3.4M | 1.22% | — | HELD |
Source: SEC EDGAR · accession 0000905148-26-002409. 13F discloses long positions only — shorts, foreign equities, and options are excluded.